文献速递血脂与心血管预防冠心病

他汀对冠状动脉钙化评分后心血管结局的影响

Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

该研究纳入无基线动脉粥样硬化性心血管疾病(ASCVD)的13,644例连续受试者,分析他汀治疗与主要不良心血管事件(MACE)的关系是否因冠状动脉钙化(CAC)评分不同而异。中位随访9.4年显示,他汀与CAC阳性者MACE风险降低相关(校正亚风险比0.76,95%CI 0.60–0.95,P=0.015),CAC阴性者无此关联(1.00,95%CI 0.79–1.27,P=0.99),且效应与CAC严重程度显著相关(交互P<0.0001)。

要点

  • CAC阳性者他汀治疗与MACE风险降低相关,CAC阴性者未见获益。
  • 他汀对MACE的效应与CAC严重程度显著相关(交互P<0.0001)。
  • 10年预防1例首次MACE的需治疗人数从CAC 1–100的100降至CAC>100的12。

核心结论

  • 在无基线ASCVD的大规模队列中,CAC的存在与严重程度可识别最可能从他汀一级预防中获益的患者。

研究设计与样本

  • 回顾性队列研究,连续纳入2002至2009年在Walter Reed Army Medical Center接受CAC评分、无既往ASCVD或恶性肿瘤的受试者,共13,644例(平均年龄50岁,71%男性),中位随访9.4年。

主要发现

  • 他汀治疗与CAC阳性患者MACE风险降低相关(校正亚风险比0.76,95%CI 0.60–0.95,P=0.015)。
  • 他汀治疗与CAC阴性患者MACE风险无关(校正亚风险比1.00,95%CI 0.79–1.27,P=0.99)。
  • 他汀对MACE的效应与CAC严重程度显著相关(交互P<0.0001)。
  • 10年预防1例首次MACE的需治疗人数从CAC 1–100的100到CAC>100的12。

临床怎么用

  • 对于无ASCVD的成人,可依据CAC评分是否存在及严重程度评估他汀一级预防的获益可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Compared with traditional risk factors, coronary artery calcium (CAC) scores improve prognostic accuracy for atherosclerotic cardiovascular disease (ASCVD) outcomes. However, the relative impact of statins on ASCVD outcomes stratified by CAC scores is unknown. OBJECTIVES: The authors sought to determine whether CAC can identify patients most likely to benefit from statin treatment. METHODS: The authors identified consecutive subjects without pre-existing ASCVD or malignancy who underwent CAC scoring from 2002 to 2009 at Walter Reed Army Medical Center. The primary outcome was first major adverse cardiovascular event (MACE), a composite of acute myocardial infarction, stroke, and cardiovascular death. The effect of statin therapy on outcomes was analyzed stratified by CAC presence and severity, after adjusting for baseline comorbidities with inverse probability of treatment weights based on propensity scores. RESULTS: A total of 13,644 patients (mean age 50 years; 71% men) were followed for a median of 9.4 years. Comparing patients with and without statin exposure, statin therapy was associated with reduced risk of MACE in patients with CAC (adjusted subhazard ratio: 0.76; 95% confidence interval: 0.60 to 0.95; p = 0.015), but not in patients without CAC (adjusted subhazard ratio: 1.00; 95% confidence interval: 0.79 to 1.27; p = 0.99). The effect of statin use on MACE was significantly related to the severity of CAC (p < 0.0001 for interaction), with the number needed to treat to prevent 1 initial MACE outcome over 10 years ranging from 100 (CAC 1 to 100) to 12 (CAC >100). CONCLUSIONS: In a largescale cohort without baseline ASCVD, the presence and severity of CAC identified patients most likely to benefit from statins for the primary prevention of cardiovascular diseases.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mitchell JD, Fergestrom N, Gage BF, et al. Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring. J Am Coll Cardiol. 2018. PMID: 30409567. doi:10.1016/j.jacc.2018.09.051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。